{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:05:54Z","timestamp":1791525954669,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale - PRIN","award":["2022ZKKWLW"],"award-info":[{"award-number":["2022ZKKWLW"]}]},{"name":"Universit\u00e0 degli Studi di Bari Aldo Moro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with multiple myeloma (MM) have an increased risk of sepsis due to underlying disease- and treatment-related immunosuppression. However, data on sepsis incidence, causative pathogens, and impact on outcomes in newly diagnosed MM (NDMM) are limited. We conducted a retrospective observational study of 92 NDMM patients who developed sepsis between 2022 and 2023 at a tertiary care center in Italy. Patient characteristics, sepsis criteria [Quick Sequential Organ Failure Assessment, Systemic Inflammatory Response Syndrome (SIRS)], microbiology results, and associations with progression-free survival (PFS) were analyzed. In this cohort of 92 critically-ill patients, pathogenic organisms were identified via microbiological culture in 74 cases. However, among the remaining 18 culture-negative patients, 9 exhibited a SIRS score of 2 and another 9 had a SIRS score of 4, suggestive of a clinical presentation consistent with sepsis despite negative cultures. Common comorbidities included renal failure (60%), anemia (71%), and bone disease (83%). Gram-negative (28%) and Gram-positive (23%) bacteria were frequent causative organisms, along with fungi (20%). Cox Univariate analyses for PFS showed statically significant HR in patients with albumin\u2009\u2265\u20093.5 vs\u2009&lt;\u20093.5 (HR\u2009=\u20095.04, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), Karnofsky performance status\u2009\u2265\u200980 vs\u2009&lt;\u200980 (HR\u2009=\u20092.01, <jats:italic>p<\/jats:italic>\u2009=\u20090.002), and early-stage vs late-stage disease by International Staging System (HR\u2009=\u20094.76 and HR\u2009=\u200912.52, both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and Revised International Staging System (R-ISS III vs R-ISS I, HR\u2009=\u20097.38, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Sepsis is common in NDMM and associated with poor outcomes. Risk stratification incorporating sepsis severity, comorbidities, and disease stage may help guide preventive strategies and optimize MM management.<\/jats:p>","DOI":"10.1007\/s10238-024-01411-2","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T16:19:44Z","timestamp":1719505184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive analysis of clinical outcomes, infectious complications and microbiological data in newly diagnosed multiple myeloma patients: a retrospective observational study of 92 subjects"],"prefix":"10.1007","volume":"24","author":[{"given":"Vanessa","family":"Desantis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fusillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatello","family":"Bochicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Solito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Cicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"issue":"1","key":"1411_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","volume":"2017","author":"MV Mateos","year":"2017","unstructured":"Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematol Am Soc Hematol Educ Program. 2017;2017(1):498\u2013507.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"1411_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3109\/10428194.2015.1088647","volume":"57","author":"J de la Rubia","year":"2016","unstructured":"de la Rubia J, Cejalvo MJ, Ribas P. Infectious complications in patients with newly diagnosed multiple myeloma: a complication from the past? Leuk Lymphoma. 2016;57(2):258\u201368.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1411_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"1411_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","volume":"117","author":"BM Russell","year":"2023","unstructured":"Russell BM, Avigan DE. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. Int J Hematol. 2023;117(5):652\u20139.","journal-title":"Int J Hematol"},{"issue":"2","key":"1411_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/ejh.13190","volume":"102","author":"R S\u00f8rrig","year":"2019","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for infections in newly diagnosed Multiple Myeloma patients: a Danish retrospective nationwide cohort study. Eur J Haematol. 2019;102(2):182\u201390.","journal-title":"Eur J Haematol"},{"issue":"8","key":"1411_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"key":"1411_CR7","doi-asserted-by":"publisher","DOI":"10.3310\/eme07100","author":"IJ Chicca","year":"2020","unstructured":"Chicca IJ, Heaney JL, Iqbal G, et al. Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study. NIHR J Libr. 2020. https:\/\/doi.org\/10.3310\/eme07100.","journal-title":"NIHR J Libr"},{"issue":"1","key":"1411_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","volume":"20","author":"C Lin","year":"2020","unstructured":"Lin C, Shen H, Zhou S, et al. Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. BMC Infect Dis. 2020;20(1):699.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"1411_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"2","key":"1411_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamaoncol.2019.5098","volume":"6","author":"S Khan","year":"2020","unstructured":"Khan S, Vaisman A, Hota SS, et al. Listeria susceptibility in patients with multiple myeloma receiving daratumumab-based therapy. JAMA Oncol. 2020;6(2):293\u20134.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1411_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707\u201310.","journal-title":"Intensive Care Med"},{"issue":"1","key":"1411_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.chest.2017.10.006","volume":"153","author":"SQ Simpson","year":"2018","unstructured":"Simpson SQ. SIRS in the time of sepsis-3. Chest. 2018;153(1):34\u20138.","journal-title":"Chest"},{"key":"1411_CR13","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primer. 2017;3:17046.","journal-title":"Nat Rev Dis Primer"},{"issue":"2","key":"1411_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/ejh.12813","volume":"98","author":"BW Teh","year":"2017","unstructured":"Teh BW, Harrison SJ, Slavin MA, Worth LJ. Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. Eur J Haematol. 2017;98(2):149\u201353.","journal-title":"Eur J Haematol"},{"key":"1411_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.624661","volume":"10","author":"M Offidani","year":"2020","unstructured":"Offidani M, Corvatta L, Mor\u00e8 S, et al. Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments. Front Oncol. 2020;10: 624661.","journal-title":"Front Oncol"},{"issue":"2","key":"1411_CR16","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143\u201361.","journal-title":"Lancet Haematol"},{"issue":"7","key":"1411_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","volume":"21","author":"C Lim","year":"2021","unstructured":"Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW. Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. Clin Lymphoma Myeloma Leuk. 2021;21(7):444-450.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"1411_CR18","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1411_CR19","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00277-021-04534-8","volume":"100","author":"F Davies","year":"2021","unstructured":"Davies F, Rifkin R, Costello C, et al. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed\/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021;100(9):2325\u201337.","journal-title":"Ann Hematol"},{"key":"1411_CR20","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncol. 2017;28:iv52\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdx096.","journal-title":"Annals Oncol"},{"issue":"4","key":"1411_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/10428194.2020.1855345","volume":"62","author":"C Geng","year":"2021","unstructured":"Geng C, Yang G, Wang H, et al. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. Leuk Lymphoma. 2021;62(4):883\u201390.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1411_CR22","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.3324\/haematol.2014.114025","volume":"100","author":"BW Teh","year":"2015","unstructured":"Teh BW, Teng JC, Urbancic K, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100(1):e28-31.","journal-title":"Haematologica"},{"key":"1411_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","volume":"191","author":"A Vacca","year":"2018","unstructured":"Vacca A, Melaccio A, Sportelli A, et al. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. Clin Immunol. 2018;191:110\u20135.","journal-title":"Clin Immunol"},{"key":"1411_CR24","unstructured":"PDTA per l\u2019Identificazione Precoce e la Gestione Tempestiva della Sepsi nel paziente adulto. In: https:\/\/www.sanita.puglia.it\/documents\/36067\/434549\/delibera+1158-2020+All.1.pdf\/47b2f3bf-42fd-407c-a5f6-997fabf411ae. Accessed 20 December 2023."},{"issue":"11","key":"1411_CR25","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143. https:\/\/doi.org\/10.1097\/CCM.0000000000005337.","journal-title":"Crit Care Med"},{"key":"1411_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.597959","author":"ZL Piedra-Quintero","year":"2020","unstructured":"Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M. CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.597959.","journal-title":"Front Immunol"},{"issue":"11","key":"1411_CR27","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1128\/IAI.00340-13","volume":"81","author":"T Lischke","year":"2013","unstructured":"Lischke T, Heesch K, Schumacher V, Schneider M, Haag F, Koch-Nolte F, Mittr\u00fccker HW. CD38 controls the innate immune response against listeria monocytogenes. Infect Immun. 2013;81(11):4091\u20139. https:\/\/doi.org\/10.1128\/IAI.00340-13.","journal-title":"Infect Immun"},{"issue":"1","key":"1411_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1286-4579(02)00055-2","volume":"5","author":"S Partida-S\u00e1nchez","year":"2003","unstructured":"Partida-S\u00e1nchez S, Randall TD, Lund FE. Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity. Microbes Infect. 2003;5(1):49\u201358. https:\/\/doi.org\/10.1016\/S1286-4579(02)00055-2.","journal-title":"Microbes Infect"},{"issue":"11","key":"1411_CR29","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1016\/S2666-7568(22)00218-5","volume":"3","author":"G Cook","year":"2022","unstructured":"Cook G, Pawlyn C, Cairns DA, Jackson GH. Defining FiTNEss for treatment for multiple myeloma. Lancet Healthy Longev. 2022;3(11):e729\u201330. https:\/\/doi.org\/10.1016\/S2666-7568(22)00218-5.","journal-title":"Lancet Healthy Longev"},{"issue":"12","key":"1411_CR30","doi-asserted-by":"publisher","first-page":"e0188988","DOI":"10.1371\/journal.pone.0188988","volume":"12","author":"R S\u00f8rrig","year":"2017","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, et al. Immunoparesis in newly diagnosed Multiple Myeloma patients: effects on overall survival and progression free survival in the Danish population. PLoS ONE. 2017;12(12):e0188988. https:\/\/doi.org\/10.1371\/journal.pone.0188988.","journal-title":"PLoS ONE"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01411-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01411-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01411-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:22:02Z","timestamp":1732987322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01411-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01411-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"It is stated that the authors have no commercial or financial arrangements that could construe their research as having a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Bari Medical School (study n\u00b0 7411, prot. n\u00b0 0073322, 26\/08\/2022). All enrolled patients provided their informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"137"}}